PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRosuvastatin
Rosuvastatin
Crestor, Rosuvastatin, Roszet (rosuvastatin) is a small molecule pharmaceutical. Rosuvastatin was first approved as Crestor on 2003-08-12. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA.
Download report
Favorite
Top Prescription Drugs
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Crestor, Rosuvastatin (discontinued: Ezallor, Rosuvastatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rosuvastatin calcium
Tradename
Company
Number
Date
Products
CRESTORAstraZenecaN-021366 RX2003-08-12
4 products, RLD, RS
Show 1 discontinued
Ezetimibe
+
Rosuvastatin calcium
Tradename
Company
Number
Date
Products
ROSZETAlthera PharmaceuticalN-213072 DISCN2021-03-23
4 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
crestorNew Drug Application2026-09-23
rosuvastatinANDA2026-11-06
rosuvastatin calciumANDA2026-11-05
rosuvastatin rosuvastatin calciumANDA2026-03-05
Agency Specific
FDA
EMA
Expiration
Code
ROSUVASTATIN CALCIUM, CRESTOR, IPR
2023-05-27ODE-118
Patent Expiration
Patent
Expires
Flag
FDA Information
Rosuvastatin Calcium, Ezallor Sprinkle, Sun Pharm
104135432036-02-12DP
Ezetimibe / Rosuvastatin Calcium, Roszet, Althera Pharms
97638852033-05-01DPU-3095
103764702033-05-01DPU-3095
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BH: Dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering
— A10BH52: Gemigliptin and rosuvastatin
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
— C10AA07: Rosuvastatin
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA06: Rosuvastatin and ezetimibe
— C10BA07: Rosuvastatin and omega-3 fatty acids
— C10BA09: Rosuvastatin and fenofibrate
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX05: Rosuvastatin and acetylsalicylic acid
— C10BX07: Rosuvastatin, amlodipine and lisinopril
— C10BX09: Rosuvastatin and amlodipine
— C10BX10: Rosuvastatin and valsartan
— C10BX13: Rosuvastatin, perindopril and indapamide
— C10BX14: Rosuvastatin, amlodipine and perindopril
— C10BX16: Rosuvastatin and fimasartan
— C10BX17: Rosuvastatin and ramipril
HCPCS
No data
Clinical
Clinical Trials
909 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———145——33151
HypercholesterolemiaD006937——69702726138
DyslipidemiasD050171——1810373027120
Coronary artery diseaseD003324—I25.12412351870
HyperlipidemiasD006949EFO_0003774E78.520615131366
HypertensionD006973EFO_0000537I1018—18121159
AtherosclerosisD050197EFO_0003914I25.1657211149
Cardiovascular diseasesD002318EFO_0000319I98348201346
Diabetes mellitusD003920EFO_0000400E08-E131043161244
Acute coronary syndromeD054058EFO_0005672—22517935
Show 99 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OverweightD050177—E66.39———110
PharmacokineticsD010599——4———15
Non-small-cell lung carcinomaD002289——4———15
MelanomaD008545——1———12
Respiratory syncytial virus infectionsD018357EFO_1001413—2————2
DiseaseD004194EFO_0000408R691———12
Crohn diseaseD003424EFO_0000384K502————2
Metabolic diseasesD008659EFO_0000589E88.91———12
MalariaD008288EFO_0001068B542————2
Alcoholic fatty liverD005235—K70.02————2
Show 55 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Muscular diseasesD009135EFO_0002970G72.9————44
Peripheral vascular diseasesD016491EFO_0003875I73.9————22
Coronary occlusionD054059—I21————11
Drug-eluting stentsD054855——————11
Endovascular proceduresD057510——————11
ContusionsD003288—T14.8————11
Genetic testingD005820——————11
ArthrogryposisD001176EFO_0003857Q74.3————11
Medication adherenceD055118EFO_0006344—————11
Treatment adherence and complianceD000074822——————11
Show 20 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRosuvastatin
INNrosuvastatin
Description
Rosuvastatin is a dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer). It has a role as an antilipemic drug, an anti-inflammatory agent, a CETP inhibitor, a cardioprotective agent, a xenobiotic and an environmental contaminant. It is a member of pyrimidines, a sulfonamide, a dihydroxy monocarboxylic acid, a statin (synthetic) and a member of monofluorobenzenes. It is functionally related to a hept-6-enoic acid. It is a conjugate acid of a rosuvastatin(1-).
Classification
Small molecule
Drug classenzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O
Identifiers
PDB—
CAS-ID287714-41-4
RxCUI—
ChEMBL IDCHEMBL1496
ChEBI ID38545
PubChem CID446157
DrugBankDB01098
UNII ID413KH5ZJ73 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Crestor – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Rosuvastatin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
44,661 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use